Can Targeting Oncogenes Be a Therapeutic Strategy?
Yes, targeting oncogenes has become a key strategy in cancer therapy. Several drugs have been developed to inhibit the activity of proteins produced by oncogenes. For example:
Tyrosine Kinase Inhibitors: Drugs like Imatinib target BCR-ABL, an oncogene product in chronic myeloid leukemia. Monoclonal Antibodies: Drugs like Trastuzumab target HER2 in breast cancer.
These targeted therapies can be more effective and have fewer side effects compared to traditional chemotherapy.
